Parenteral Drugs (India) Ltd

Parenteral Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Parenteral Drugs (India) Ltd

₹ 2.90 -10.49%
21 Aug 2023
pdindia.com BSE: 524689 NSE: PDPL
About

Incorporated in 1983, Parenteral Drugs Ltd
is engaged in Manufacturing and Trading of Pharmaceutical Products

Key Points

Product Profile:[1]
a) IV Fluids:[2] Carbohydrate and Electrolytes, Diuretics, Dialysis & Irrigation Solution, Anti-infective & Anti-fungal
b) Oncology:[3] Injections, Tablets and Capsules
c) Anaesthesia:[4] Sevoplan, Isoplan

Website BSE NSE - BZ
  • Market Cap ₹ 8.65 Cr.
  • Current Price ₹ 2.90
  • High / Low ₹ /
  • Stock P/E
  • Book Value ₹ -276
  • Dividend Yield 0.00 %
  • ROCE %
  • ROE %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -48.3% over past five years.
  • Contingent liabilities of Rs.135 Cr.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
2 9 7 7 9 3 5 2 3 3 2 1 2
12 13 11 10 13 9 11 5 -1 6 6 5 8
Operating Profit -9 -4 -4 -3 -4 -6 -6 -3 3 -3 -3 -3 -6
OPM % -387% -46% -50% -41% -48% -200% -139% -141% 132% -90% -139% -224% -333%
1 0 0 0 0 0 0 0 0 0 0 0 52
Interest 25 26 27 28 29 30 31 32 32 34 35 37 0
Depreciation 55 4 4 4 4 4 4 4 4 4 4 4 27
Profit before tax -88 -34 -35 -35 -37 -40 -42 -39 -33 -41 -43 -44 19
Tax % -18% -19% -19% -26% -13% -19% -19% -21% -26% -22% -22% -22% -24%
-72 -28 -28 -26 -32 -32 -34 -31 -25 -32 -34 -35 24
EPS in Rs -24.13 -9.29 -9.49 -8.77 -10.71 -10.81 -11.29 -10.39 -8.33 -10.75 -11.27 -11.58 7.99
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
482 333 327 274 263 260 230 224 32 32 12 8
433 319 341 349 248 296 249 225 50 47 24 24
Operating Profit 50 14 -14 -75 14 -36 -19 -1 -18 -15 -12 -15
OPM % 10% 4% -4% -27% 5% -14% -8% -1% -55% -46% -97% -177%
1 0 0 107 1 2 3 2 1 0 0 52
Interest 29 48 56 60 70 70 86 98 96 110 125 106
Depreciation 13 14 23 19 31 23 25 24 69 17 17 40
Profit before tax 9 -49 -93 -47 -86 -127 -127 -121 -181 -142 -154 -109
Tax % 46% 10% 16% -3% -22% -8% -8% -8% -18% -20% -21% -30%
5 -53 -108 -45 -68 -117 -118 -112 -148 -114 -122 -76
EPS in Rs 1.71 -20.64 -41.69 -15.15 -22.69 -39.09 -39.52 -37.50 -49.61 -38.26 -40.82 -25.61
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -31%
5 Years: -48%
3 Years: -36%
TTM: -30%
Compounded Profit Growth
10 Years: %
5 Years: -2%
3 Years: 4%
TTM: -6%
Stock Price CAGR
10 Years: -18%
5 Years: 1%
3 Years: -11%
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity Capital 26 26 26 30 30 30 30 30 30 30 30 30
Reserves 300 311 203 157 82 278 -47 -166 -477 -591 -713 -854
332 395 501 539 581 670 772 767 638 636 636 107
97 118 105 98 92 88 159 260 349 478 615 1,201
Total Liabilities 755 850 835 825 785 1,066 914 890 541 552 568 484
406 500 610 571 542 892 739 716 356 339 322 205
CWIP 79 116 4 1 0 0 0 0 0 0 0 0
Investments 4 0 0 0 0 0 1 0 2 2 2 2
267 233 221 253 242 174 175 175 182 210 244 276
Total Assets 755 850 835 825 785 1,066 914 890 541 552 568 484

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
78 20 -168 -60 2 58 134 167 477 112 125 -0
-113 -147 -18 33 3 -110 -1 -1 97 0 0 65
31 133 182 25 -10 54 -134 -167 -574 -112 -125 -64
Net Cash Flow -5 5 -3 -2 -5 1 -0 -0 0 0 -0 -0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 81 101 88 161 194 130 99 6 0 0 0 0
Inventory Days 118 149 121 128 232 112 107 68 224 73 103 69
Days Payable 79 157 112 99 177 77 101 130 671 458 504 654
Cash Conversion Cycle 120 93 97 189 249 164 105 -55 -446 -385 -401 -585
Working Capital Days 106 103 115 133 144 15 -248 -560 -9,244 -10,747 -32,260 -48,682
ROCE % 6% -0% -5% -4% -2% -7% -5% -3% -21% -24% -213%

Shareholding Pattern

Numbers in percentages

Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022
73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.29%
0.01% 0.01% 0.03% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
26.71% 26.71% 26.69% 26.71% 26.71% 26.71% 26.71% 26.71% 26.71% 26.71% 26.71% 26.71%
No. of Shareholders 7,3967,3787,3307,2967,2957,3007,3007,2697,2057,1837,1647,129

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports